A GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF EFGARTIGIMOD PH20 SC IN ADULT AND ADOLESCENT PARTICIPANTS WITH AUTOIMMUNE ENCEPHALITIS

Registry ID

ARGX-113-22-AIE-2001

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ARGENX BV

Last update

2026-06-26

Conditions

• AUTOIMMUNE ENCEPHALITIS

View on source registry